We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Commercial Assays Detect Fungal DNA in Bronchoalveolar Lavage

By LabMedica International staff writers
Posted on 23 Apr 2012
The performance of two commercially available molecular assays for the detection of Aspergillus and Pneumocystis DNA has been investigated. More...


The assays are based on real-time polymerase chain reactions (PCR), were tested on bronchoalveolar lavage fluid, and were compared to reference diagnostic tests, including culture, and additional molecular analysis by real-time PCR, nested PCR, and sequencing was also performed.

At the University of Modena and Reggio Emilia (Italy) 20 patients were retrospectively enrolled in a study and clustered into three groups: seven patients with invasive aspergillosis group (IA), eight patients Pneumocystis jirovecii pneumonia (PCP), and five patients acted as a negative control group. Twenty-one samples were obtained from direct bronchoalveolar lavage (BAL) procedures required for clinical assessment, while one sample was obtained by lung biopsy.

Fungal DNA was extracted from the samples using the MycXtra Fungal DNA Extraction Kit and assessed by the MycAsp Assay and by MycPCP Assay, all of which are products of Myconostica (Cambridge, UK). The real-time PCR (RT-PCR) was carried out on the ABI 7300 platform. The Platelia Aspergillus commercial galactomannan enzyme-linked immunosorbent assay (GM-ELISA, Bio-Rad Laboratories; Hercules, CA, USA) and the MeriFluor Pneumocystis, immunofluorescence assay (Meridian Bioscience; Cincinnati, OH, USA) were also performed.

All the IA patients were MycAsp Assay positive, whereas 12 non-IA patients returned negative PCR results and, 7 of 8 PCP patients were MycPCP Assay positive, while 9 non-PCP patients were PCR negative. The results of the study provide the first evidence on the efficacy of the MycAsp Assay and MycPCP Assay in discriminating between BAL positive and BAL negative for Aspergillus or Pneumocystis DNA, when using the ABI 7300 platform (Applied Biosystems; Foster City, CA, USA).

The authors concluded that the study provides a step forward towards the inclusion of molecular methods in the routine assessment of biological samples, especially from critical patients in whom rapid and sensitive approaches are needed to fulfill a prompt and precise diagnosis. The study was published online on April 16 2012 in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
University of Modena and Reggio Emilia
Myconostica
Bio-Rad Laboratories



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.